Northwest Biotherapeutics Q2 2026 Earnings Report

Northwest Biotherapeutics EPS Results

• Actual EPS: -$0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Northwest Biotherapeutics Revenue Results

• Actual Revenue: $0.81 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Northwest Biotherapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Northwest Biotherapeutics (OTCMKTS:NWBO) is a biotechnology company focused on developing personalized cancer immunotherapies. Its lead platform uses a patient’s own dendritic cells, which are immune cells collected from the patient and prepared to recognize and stimulate an immune response against tumor tissue.

The company’s principal investigational product is DCVax-L, an autologous dendritic-cell vaccine designed for patients with glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational treatment intended for injection directly into inoperable solid tumors. These products remain investigational and are not broadly approved cancer treatments.

Northwest Biotherapeutics has conducted clinical development activities in the United States and Europe, including the United Kingdom and Germany. The company has worked with manufacturing and clinical partners in the United Kingdom, where its personalized vaccine manufacturing operations have been based. Linda Powers has served as the company’s chief executive officer and chairwoman.